Anti-CD19 antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8337840
APP PUB NO 20120189542A1
SERIAL NO

13398214

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IMMUNOMEDICS, INC.MORRIS PLAINS, NJ317

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Goldenberg, David M Mendham, US 431 6311
Hansen, Hans J Picayune, US 203 3112
Qu, Zhengxing Warren, US 83 1181

Cited Art Landscape

Patent Info (Count) # Cites Year
 
EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC (1)
2003/0133,939 Binding domain-immunoglobulin fusion proteins 148 2002
 
Consorzio per la Ricerca sulla Microelettronica nel Mezzogiorno (1)
5798554 MOS-technology power device integrated structure and manufacturing process thereof 68 1996
 
GENENTECH, INC. (1)
2008/0187,966 Antibodies and methods for making and using them 35 2007
 
IMMUNOMEDICS, INC. (7)
6183744 Immunotherapy of B-cell malignancies using anti-CD22 antibodies 131 1998
6187287 Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells 132 1998
6306393 Immunotherapy of B-cell malignancies using anti-CD22 antibodies 233 1999
6653104 Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells 100 2001
2003/0133,930 Immunotherapy of autoimmune disorders using antibodies which target B-cells 42 2003
7109304 Humanized anti-CD19 antibodies 25 2004
7462352 Methods of treatng B-cell diseases using humanized anti-CD19 antibodies 18 2006
 
PROTEIN DESIGN LABS, INC. (1)
5530101 Humanized immunoglobulins 1189 1990
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5686072 Epitope-specific monoclonal antibodies and immunotoxins and uses thereof 121 1994
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
IMMUNOMEDICS, INC. (2)
* 2015/0252,110 Anti-CD19 Antibodies 0 2015
9605071 Anti-CD19 antibodies 0 2016
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 25, 2020
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 25, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00